Literature DB >> 19301686

Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Georgia Pambianco1, Manuel Lombardero, Vera Bittner, Alan Forker, Frank Kennedy, Ashok Krishnaswami, Arshag D Mooradian, Rodica Pop-Busui, Jamal S Rana, Annabelle Rodriguez, Michael Steffes, Trevor J Orchard.   

Abstract

In order to examine lipids, a major treatment parameter in those with diabetes and heart disease, the authors analyzed baseline data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. The study consisted of 2368 participants with type 2 diabetes and coronary artery disease from 49 sites in 6 countries (2295 provided lipid measurements). Fifty-nine percent of participants had a low-density lipoprotein (LDL) cholesterol level < 100 mg/dL. Levels of total, LDL, and non-high-density lipoprotein (HDL) cholesterol and triglycerides differed by age group (younger than 55, 55-64, and 65 years and older); they were lowest in those aged 65 years. Women had higher total, LDL, and non-HDL cholesterol values. Education was associated with lower total, LDL, and non-HDL cholesterol levels. LDL cholesterol and triglyceride values were lower in the United States and Canada. Adjustment for age, sex, education level, randomization year, and medication did not eliminate these differences. Geographic variation was seen and was not fully accounted for by demographic or treatment characteristics (all P values < .05).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19301686      PMCID: PMC2717619          DOI: 10.1111/j.1751-7141.2008.00014.x

Source DB:  PubMed          Journal:  Prev Cardiol        ISSN: 1520-037X


  28 in total

1.  Heparin--Mn2+ quantitation of high-density-lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples.

Authors:  G R Warnick; J J Albers
Journal:  Clin Chem       Date:  1978-06       Impact factor: 8.327

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  Enzymatic determination of total serum cholesterol.

Authors:  C C Allain; L S Poon; C S Chan; W Richmond; P C Fu
Journal:  Clin Chem       Date:  1974-04       Impact factor: 8.327

4.  Quantitative determination of serum triglycerides by the use of enzymes.

Authors:  G Bucolo; H David
Journal:  Clin Chem       Date:  1973-05       Impact factor: 8.327

5.  A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

Authors:  Elaine Chiquette; Gilbert Ramirez; Ralph Defronzo
Journal:  Arch Intern Med       Date:  2004-10-25

6.  Compliance with recommendations for lipid management among patients with type 2 diabetes in an academic family practice.

Authors:  Gavin Putzer; Richard Roetzheim; Arnold M Ramirez; Kevin Sneed; H J Brownlee; Robert J Campbell
Journal:  J Am Board Fam Pract       Date:  2004 Mar-Apr

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

Review 8.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

9.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts).

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Atherosclerosis       Date:  2004-04       Impact factor: 5.162

10.  Thiazolidinediones and blood lipids in type 2 diabetes.

Authors:  Jeroen P H van Wijk; Eelco J P de Koning; Edwin P Martens; Ton J Rabelink
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-08-07       Impact factor: 8.311

View more
  3 in total

1.  Understanding gender differences in statin use among elderly Medicare beneficiaries: an application of decomposition technique.

Authors:  Sandipan Bhattacharjee; Patricia A Findley; Usha Sambamoorthi
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

2.  Health Professional Shortage Areas, insurance status, and cardiovascular disease prevention in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Todd M Brown; Gaurav Parmar; Raegan W Durant; Jewell H Halanych; Martha Hovater; Paul Muntner; Ronald J Prineas; David L Roth; Tandaw E Samdarshi; Monika M Safford
Journal:  J Health Care Poor Underserved       Date:  2011-11

Review 3.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.